Genmab — Februar 2019
-
Jaja enig.... Det var måske en forkert måde at udtrykke sig på. Men meningen er jo at så længe der "kun" er Dara at forholde sig til. Så længe er det den eneste faktor analytikere etc. kan forholde sig til..... Og derfor er det efter min mening en MEGET vigtig faktor at der kommer nogle aftaler i hus
-
ja - vi savner noget validering
-
New trial by Incyte corporation: INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma - INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
-
-
-
we were told we would get "an early peak at data from Griffin" ; the trial shows it reached the primary completion date in january. https://clinicaltrials.gov/ct2/history/NCT02874742?A=26&B=27&C=merged
-
Abbvie comes to the multiple myeloma party late / JNJ-7957
-
ok, so JNJ actually states "Splitting the first dose of DARZALEX over two consecutive days effectively reduced the duration of the first infusion …" https://www.jnj.com/u-s-fda-approves-darzalex-daratumumab-split-dosing-regimen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind